EU panels backs approval of Ariad's Iclusig for leukemia

03/25/2013 | American City Business Journals

Ariad Pharmaceuticals' Iclusig, or ponatinib, was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for chronic, accelerated or blast-phase chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care